Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03328208 · ClinicalTrials.gov registry record · NA

Nonpharmacologic Reduction of Periprocedural Distress and Drug Use

A NA study, sponsored by Hypnalgesics.

Completed
Registry status
NA
Development phase
72
Enrollment target

NCT03328208 is a NA study that has completed, run by Hypnalgesics. The registered enrollment target is 72 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03328208, a NA study, has completed, sponsored by Hypnalgesics.

COMPLETED
Registry status
NA
Development phase
72 participants
Enrollment target

Study Summary

Objectives of this Phase I pilot trial are to provide data towards assessing and facilitating feasibility of a larger scale Phase II trial in which the effects of a calmative Comfort Talk® app can be unequivocally evaluated. Towards this goal we will pursue following outcome parameters for Phase I: Feasibility/acceptability assessment: Primary outcome parameter: • ability to obtain complete on-site data sets from at least 90% of patients enrolled (with at least 40% from patients in the app group and at least 40% from patients in the control group). Secondary outcome parameters: * ability to enroll 60 patients by day 150 after initiation of recruitment in the clinic (=day 1) * obtain 38 packages of filled out diary cards (at least 16 from patients in the app group and at least 16 from patients in the control group) * 90% of patients in app group listen to app ≥5 min Phase II preparation primary outcome parameter • anxiety at the end of the waiting room time Secondary outcome parameters * pain the end of the waiting room time * anxiety during treatment * pain during treatment * anxiety during 1 week after treatment * pain during 1 week after treatment * use of units of sedatives and analgesics during 1 week after treatment (assessed by prescription at end of the visit) * patient satisfaction

Interventions

  • OTHER Comfort Talk® app
  • OTHER White Noise app

Trial Details

FieldValue
Enrollment Target 72 participants
Start Date 2017-11-22
Est. Completion 2018-12-31
Phase NA

Sponsor

Hypnalgesics

3 total trials

What the Registry Record Tells You About NCT03328208

The ClinicalTrials.gov registry entry for NCT03328208 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hypnalgesics, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Comfort Talk® app is the first listed.

NCT03328208 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03328208 about?

NCT03328208 is a clinical study titled "Nonpharmacologic Reduction of Periprocedural Distress and Drug Use". Objectives of this Phase I pilot trial are to provide data towards assessing and facilitating feasibility of a larger scale Phase II trial in which the effects of a calmative Comfort Talk® app can be unequivocally evaluated. Towards this goal we will pursue following outcome parameters for Phase I...

What is the current status of trial NCT03328208?

This trial is currently completed. It is a NA study. The enrollment target is 72 participants. The study started on 2017-11-22. Estimated completion is 2018-12-31.

What interventions are being tested in trial NCT03328208?

The interventions under investigation include: Comfort Talk® app (OTHER), White Noise app (OTHER).

Who is sponsoring clinical trial NCT03328208?

This trial is sponsored by Hypnalgesics, which has 3 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.